17,261 trials
Melanoma
Primary: Number of Patients With Objective Tumor Response (OR) to GSK2132231A Study Treatment — 2; 0; 0; 1 Participants
Childhood Glaucoma
Primary: Percentage of Eyes With Response — 33 eyes
Cardiac Disease
Primary: Total Sedation Requirements — 325; 1158 milligrams
Melanoma
Primary: Best Overall Objective Response Rate (ORR) by Modified "Skin" RECIST — 32.1; 25.0; 25.0 percentage of participants
Severe Traumatic Brain Injury
Primary: Fraction of Time That Brain Oxygen Levels Are Below the Critical Threshold of 20 mm Hg . — 0.15; 0.44 Proportion
Temporomandibular Disorder
Primary: Change From Baseline in Visual Analogic Scale (VAS) for Pain — 4.1; 4.4; 5.2; 3.3 millimeters — p=<0.001
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Overall Survival — 574; 552 days — p=0.923
Metastatic Renal Cell Carcinoma
Primary: Clinical Response - IL-2 Combined With Hydroxychloroquine (HCQ) at Either 1,200 mg/d or 600 mg/d) (All Patients) — 9; 14; 3; 3 Participants
Metastatic Colorectal Cancer
Primary: Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination) — 373.00; 370.00 days — p=0.967
Radial Artery
Primary: Radial Artery Cross Sectional Area — 3.4; 3.0 mm^2
Coronary Heart Disease
Primary: Myocardial Perfusion — 1.83; 1.52 myocardial perfusion index
Leukemia
Primary: Maximum Tolerated Dose (MTD) of Bendamustine Combined With Fixed-Dose Fludarabine and Rituximab (FBR) — 30 mg/m^2
Vaginal Atrophy
Primary: Change From Baseline to Week 12 in the Severity of Vaginal Dryness — 15; 13; 13; 9 Participants — p==0.304
HIV
Primary: Total HIV DNA From CD4 T-cells — 2.95; 3.06 HIV-DNA copies/mill CD4+ T cells (log10) — p=0.26
Healthy Participants
Primary: Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera — 80; 75; 100; 100 percentage of participants